Results of the first-in-human study of ABBV-075 (mivebresib), a pan-inhibitor of bromodomain (BD) and extra terminal (BET) proteins, in patients (pts) with relapsed/refractory (R/R) solid tumors.

被引：4
|
作者：
Piha-Paul, Sarina Anne
Sachdev, Jasgit C.
Barve, Minal A.
LoRusso, Patricia
Szmulewitz, Russell Zelig
Patel, Sapna Pradyuman
McKee, Mark D.
Wolff, Johannes E.
Hu, Beibei
Sood, Anjla
Chen, Xiaotian
Wilson, Sarah C.
O'Neil, Bert H.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] HonorHealth Res Inst TGen, Scottsdale, AZ USA
[3] Mary Crowley Canc Res Ctr, Dallas, TX USA
[4] Yale Canc Ctr, New Haven, CT USA
[5] Univ Chicago, Chicago, IL 60637 USA
[6] AbbVie Inc, N Chicago, IL USA
[7] Indiana Univ Sch Med, Indianapolis, IN 46202 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.2510
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2510
引用
收藏
页数：1
相关论文
共 50 条
  • [1] First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors
    Piha-Paul, Sarina A.
    Sachdev, Jasgit C.
    Barve, Minal
    LoRusso, Patricia
    Szmulewitz, Russell
    Patel, Sapna Pradyuman
    Lara, Primo N., Jr.
    Chen, Xiaotian
    Hu, Beibei
    Freise, Kevin J.
    Modi, Dimple
    Sood, Anjla
    Hutti, Jessica E.
    Wolff, Johannes
    O'Neil, Bert H.
    CLINICAL CANCER RESEARCH, 2019, 25 (21) : 6309 - 6319
  • [2] First-In-Human Study of ABBV-075 (Mivebresib), A Pan-Inhibitor of Bromodomain and Extra Terminal (BET) Proteins, in Patients (Pts) With Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML): Preliminary Data
    Borthakur, Gautam
    Wolff, Johannes
    Aldoss, Ibrahim
    Hu, Beibei
    Minh Dinh
    Torres, Alison
    Chen, Xiaotian
    Rizzieri, David
    Sood, Anjla
    Odenike, Olatoyosi
    Jonas, Brian A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S203 - S203
  • [3] Results from the first-in-human study of mivebresib (ABBV-075), a pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed/refractory acute myeloid leukemia.
    Odenike, Olatoyosi
    Wolff, Johannes E.
    Borthakur, Gautam
    Aldoss, Ibrahim Taha
    Rizzieri, David
    Prebet, Thomas
    Hu, Beibei
    Minh Dinh
    Chen, Xiaotian
    Modi, Dimple
    Freise, Kevin J.
    Jonas, Brian Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] First-in-human study of ABBV-075 (mivebresib), a pan-inhibitor of bromodomain and extra terminal (BET) proteins, in patients (pts) with relapsed/refractory (RR) acute myeloid leukemia (AML): Preliminary data.
    Borthakur, Gautam
    Wolff, Johannes E.
    Aldoss, Ibrahim
    Hu, Beibei
    Minh Dinh
    Torres, Alison
    Chen, Xiaotian
    Rizzieri, David
    Sood, Anjla
    Odenike, Olatoyosi
    Jonas, Brian Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Uveal melanoma patients (pts) treated with abbv-075 (mivebresib), a pan-inhibitor of bromodomain and extraterminal (BET) proteins: Results from a phase 1 study.
    Patel, Sapna Pradyuman
    Wolff, Johannes E.
    Mostorino, Rosa Margarita
    Chen, Xiaotian
    McKee, Mark D.
    Piha-Paul, Sarina Anne
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Gene expression and cytokine modulation in a first in human (FIH) study of a pan BET inhibitor ABBV-075 in solid tumors.
    O'Neil, Bert H.
    Modi, Dimple
    LoRusso, Patricia
    Wong, Shekman
    Motwani, Monica
    Sachdev, Jasgit C.
    Wolff, Johannes E.
    Patel, Sapna Pradyuman
    Hu, Beibei
    Szmulewitz, Russell Zelig
    Sood, Anjla
    Barve, Minal A.
    McKee, Mark D.
    Piha-Paul, Sarina Anne
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia
    Borthakur, Gautam
    Odenike, Olatoyosi
    Aldoss, Ibrahim
    Rizzieri, David A.
    Prebet, Thomas
    Chen, Chris
    Popovic, Relja
    Modi, Dimple A.
    Joshi, Rujuta H.
    Wolff, Johannes E.
    Jonas, Brian A.
    CANCER, 2021, 127 (16) : 2943 - 2953
  • [8] CC-90010, a reversible, oral bromodomain and extra-terminal (BET) inhibitor in patients (Pts) with advanced solid tumours (STs) and relapsed/refractory (R/R) non-Hodgkin lymphoma: Updated results of a phase I study
    Moreno, V.
    Brana, I.
    Sepulveda Sanchez, J. M.
    Vieito, M.
    Hernandez-Guerrero, T.
    Doger, B.
    Saavedra, O.
    Carlo-Stella, C.
    Michot, J-M.
    Italiano, A.
    Musuraca, G.
    Sarmiento, R.
    Amoroso, B.
    Mora, S.
    Sanchez-Perez, T.
    Aronchik, I.
    Filvaroff, E.
    Hanna, B.
    Nikolova, Z.
    Pinto, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S463 - S464
  • [9] Phase I first-in-man trial of a novel bromodomain and extra-terminal domain (BET) inhibitor (BI 894999) in patients (Pts) with advanced solid tumors.
    Aftimos, Philippe Georges
    Bechter, Oliver
    Awada, Ahmad
    Jungels, Christiane
    Dumez, Herlinde
    Huyvaert, Nathalie
    Costermans, Jo
    Lee, Chooi
    Meeus, Marie-Anne
    Burkard, Ute
    Musa, Hanny
    Zhao, Yihua
    Schoffski, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] First-in-human phase I study of ABBV-637 as monotherapy and in combination in patients with relapsed and refractory solid tumors
    Rotow, J.
    Yoh, K.
    Powderly, J. D.
    Shimizu, T.
    Perets, R.
    Paz-Ares, L.
    Phillips, A.
    Souers, A.
    Ansell, P. J.
    Jin, J.
    Badawi, M.
    Saab, R.
    Morrison-Thiele, G.
    Jeffries, S.
    Aristide, M. R. Neagu
    Carneiro, B. A.
    Papadopoulos, K. P.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1090 - S1090
12345